Click on image to view larger version.

Figure 6 Effect of mevalonate (MVA) or isoprenoids on Fas ligand (FasL) expression and solubilized Fas ligand (sFasL) released by human cultured endothelial cells (ECs). Endothelial cells were preincubated for 2 h with atorvastatin (Atv), mevalonate, or isoprenoids and then 6 h with tumor necrosis factor (TNF)-alpha (25 ng/ml). (A) Western blot showing the effect of mevalonate, farnesyl pyrophosphate (FPP), or geranylgeranyl pyrophosphate (GGPP) on FasL expression in ECs. (B) Mevalonate and GGPP decreased sFasL release by ECs in the presence of atorvastatin (*p < 0.05 vs. atorvastatin).